Co-Authors
This is a "connection" page, showing publications co-authored by Lennie Derde and Anthony Gordon.
Connection Strength
1.665
-
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021 09 16; 385(12):1147-1149.
Score: 0.963
-
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 04 22; 384(16):1491-1502.
Score: 0.233
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021 08 10; 326(6):499-518.
Score: 0.060
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):790-802.
Score: 0.060
-
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):777-789.
Score: 0.060
-
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug; 47(8):867-886.
Score: 0.060
-
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 May 14; 12(1):3001.
Score: 0.059
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.059
-
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 10 06; 324(13):1317-1329.
Score: 0.057
-
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020 07; 17(7):879-891.
Score: 0.056